TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05614102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2965501
Description: Daily oral application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2965501
Description: Daily oral application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In combination group 200mg as infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In combination group 200mg as infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: Standard of care doses per tumor type will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: Standard of care doses per tumor type will be administered.
Study: NCT06054555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 206
Description: ABP 206 will be given intravenously over a period of 30 or 60 minutes, every 4 weeks (Q4W) for a total of 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be given intravenously over a period of 30 or 60 minutes, Q4W for a total of 24 months.
Study: NCT06257706

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vedolizumab
Description: All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vedolizumab
Description: All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.
Study: NCT06349941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Movn app
Description: Participants will receive a FitBit accelerometer to monitor physical activity. Participants will have a 2 week run-in period where physical activity levels will be monitored followed by a 12-week home-based exercise program delivered via a previously validated, commercially available smartphone platform called Movn (Moving Analytics, California)
Study: NCT06470048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ianalumab
Description: subcutaneous (s.c.) injection as defined in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: subcutaneous (s.c.) injection as defined in the protocol
Study: NCT04867187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: 20 minutes of high frequency (20Hz) rTMS.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: 20 minutes of high frequency (20Hz) rTMS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy using virtual reality
Description: active mirror-based therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mirror therapy using sham mirror
Description: 20 minutes of sham mirror-based therapy
Study: NCT05322408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCW9218
Description: HCW9218 at the assigned dose level is administered as a subcutaneous injection once every 3 weeks for a minimum of 2 treatment cycles unless medically contraindicated.
Study: NCT06503289

Intervention type: DEVICE
Intervention: Cytosorb therapy
Description: Extracorporeal treatment with cytosorb filter to patients diagnosed with rhabdomyolysis
Study: NCT05607550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furmonertinib 240 mg oral, daily
Description: furmonertinib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furmonertinib 160 mg oral, daily
Description: furmonertinib tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platinum-based chemotherapy
Description: (carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
Study: NCT05251753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-Lock
Description: Patients will be randomized to either A) left side K-Lock with right side suture-based technique or B) right side K-Lock with left side suture-based technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-Lock
Description: Patients will be randomized to either A) left side K-Lock with right side suture-based technique or B) right side K-Lock with left side suture-based technique.
Study: NCT06550752

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: UC-MSCs and PRP
Description: UC-MSCs are progenitor cells that can differentiate into various types of cells in the body and have the ability to regenerate and repair damaged tissue. During repair and regeneration, these cells secrete expedient and powerful bioactive paracrine factors including cytokines, chemokines, collagen, fibronectin, and growth factors promoting tissue repair, angiogenesis, and the regeneration of nerve cells as well as regulating cellular pathways including immunomodulation and inflammatory responses. Additionally, PRP contains numerous growth factors and cytokines, including vascular endothelial growth factor (VEGF), transforming growth factor beta-1 and beta-2 (TGF-β1/2), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), interleukin 8 and matrix metalloproteinases 2,9. The combined effect of these factors provided by PRP injections is proposed to have anti- inflammatory, reparative, neuroprotective and neurotrophic effects that contribute to the treatment of ED.
Study: NCT06411769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: In this intervention, participants will received notifications onto the Pathverse app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: In this intervention, participants will received notifications onto the Pathverse app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: In this intervention, participants will received notifications onto the Pathverse app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual
Description: In this Phase 2 individual-level intervention, participants will receive remote education modules and one-to-one monthly phone-based coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual
Description: In this Phase 2 individual-level intervention, participants will receive remote education modules and one-to-one monthly phone-based coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School
Description: In this Phase 2 school-level intervention, participants will receive group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and participate in work time/weekend group walks/hikes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School
Description: In this Phase 2 school-level intervention, participants will receive group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and participate in work time/weekend group walks/hikes.
Study: NCT06378047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immunotherapy that will be administered via IV infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: Participants will undergo IRE as standard of care treatment.
Study: NCT06370182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANA Funnel Catheter
Description: Mechanical thrombectomy using a stent retriever delivered by the ANA device that enables local flow restriction when deployed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter with or without an intermediate catheter and aspiration per conventional techniques.
Study: NCT05079919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olezarsen-matching placebo will be administered by SC injection.
Study: NCT04939935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Extended release metformin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo is inactive tablets that is identical to the intervention Metformin tablets.
Study: NCT05493709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide
Description: All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
Study: NCT04770402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 12 acupuncture sessions over 10 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care CIPN management
Description: Investigator directed standard of care management of CIPN
Study: NCT05854251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subjects receive an s.c. injection of 100 mg Anakinra on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.67 ml of s.c. injection of saline will be taken on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
Study: NCT06253494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdHER2DC vaccine
Description: AdHER2DC vaccine is given by intradermal injections on Day 1 of cycles 1-3 (priming) followed by optional boost doses (up to 3), on Day 1 of cycles 6, 9, 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdHER2DC vaccine
Description: AdHER2DC vaccine is given by intradermal injections on Day 1 of cycles 1-3 (priming) followed by optional boost doses (up to 3), on Day 1 of cycles 6, 9, 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is given by IV infusion on Day 8 of cycle 1 and Day 1 of cycles 2-16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is given by IV infusion on Day 8 of cycle 1 and Day 1 of cycles 2-16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 is given by subcutaneous injections on Day 1 of cycles 1-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is taken orally on Days 8-28 on cycle 1 and every day of cycles 2-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is taken orally on Days 8-28 on cycle 1 and every day of cycles 2-16

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PATHWAY HER2 (4B5) assay
Description: Used during screening to estimate eligibility

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PATHWAY HER2 (4B5) assay
Description: Used during screening to estimate eligibility
Study: NCT06429735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N1 Implant
Description: The N1 Implant is a type of implantable brain-computer interface

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R1 Robot
Description: The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
Study: NCT06356259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX-010
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX-010
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT05762302

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MeMed BV test
Description: Following the MeMed BV test result, the clinician will decide whether or not to prescribe an antibiotic for your condition
Study: NCT06402669

Intervention type: OTHER
Intervention: Packed Red Blood Cell Administration
Description: Difference in occurrence of mortality in patients transferred versus directly admitted who have packed red blood cell administration in the first four hours of arrival to the hospital.

Intervention type: OTHER
Intervention: Packed Red Blood Cell Administration
Description: Difference in occurrence of mortality in patients transferred versus directly admitted who have packed red blood cell administration in the first four hours of arrival to the hospital.
Study: NCT04811040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teropavimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teropavimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teropavimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teropavimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinlirvimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinlirvimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinlirvimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinlirvimab
Description: Administered intravenously
Study: NCT06106607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: A 20-week intervention with a basic part, including~1. A group session with education about IBD,physical activity and exercise in relation to IBD (definitions, evidence and recommendations). Furthermore, access to a video with general information about IBD, physical activity and exercise~2. Four individual motivational counselling sessions (two physical, two by telephone) with a project nurse. These will involve identifying individual motivation and opportunities for increasing physical activity and behavioral goal setting.~An optional intervention part will follow, including choises between (or all of)~1. A one-hour individual session with a physiotherapist, involving guidance in physical activity and exercise tailored to the individual.~2. Being teamed up with 1-2 'exercise buddies' (other participants from the overall intervention group).~3. Access to 4 short 2-3 minutes videos/'reels' of a physiotherapist explaining and demonstrating beneficial physical exercises.
Study: NCT06159725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMTX-101
Description: CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMTX-101
Description: CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMTX-101
Description: CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.
Study: NCT06352658

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mandibular advancement device
Description: With a vacuum mahine (Biostar, NY) a 2-mm-thick hard, clear resin sheet was adapted to the cast. The excess material was cut, borders were trimmed and smoothed. Maxillary mandibular casts were mounted by a protrusive the interocclusal record. The appliances were re-placed on the mounted casts to be splinted to form a Monoblock MAD by autopolymerizing acrylic resin at the premolar -molar area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD CAM mandibular advancement device
Description: 3D models for the stone casts were constructed with laser scanning machine (accuracy \<20 µm; D500, 3shape).~Maxillary and mandibular casts were rescanned in the achieved 75% advancement position and monoblock device was designed by CAD (computer-aided design) with 3D software (3-matic; Materialise) and printed by

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uvuloplatopharyngeoplasty UPPP
Description: uvulopalatopharyngeoplasty UPPP were performed by the same ENT surgeon under GA.
Study: NCT05808140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Preoperatively, a single dose of intravenous indocyanine green is administered
Study: NCT05859412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic exercises
Description: The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection (Depomedrone 40mg)
Description: Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome

Intervention type: OTHER
Group type: OTHER
Intervention: Advice
Description: Group receiving advice but no additional treatment
Study: NCT05127473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 10 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 100 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 100 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 100 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 100 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
Study: NCT05808140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Preoperatively, a single dose of intravenous indocyanine green is administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Preoperatively, a single dose of intravenous indocyanine green is administered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging
Description: Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging
Description: Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging
Description: Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively
Study: NCT06485856

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Description: Evaluation of the pain level of patients who are followed in intensive care and cannot speak during the procedural procedure with 3 different methods.
Study: NCT06232603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education of medication management
Description: Video and handout materials will be provided
Study: NCT06299410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 10 mg
Description: ITI-1284 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 20 mg
Description: ITI-1284 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 20 mg
Description: ITI-1284 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 20 mg
Description: ITI-1284 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 20 mg
Description: ITI-1284 tablet
Study: NCT05523206

Intervention type: OTHER
Intervention: No intervention
Description: No intervention